The administration of President Donald Trump announced this Tuesday that federal funds from Medicaid and the Children's Health Insurance Program (CHIP) will no longer be used to finance gender-affirming treatments for minors, as part of a new policy that restricts access to this type of medical care in the United States.

Trump reported the measure through his official Truth Social account and stated that American taxpayers will no longer pay for “sex reassignment surgeries or hormones for children.”

The new regulations were promoted by the Centers for Medicare and Medicaid Services (CMS), under the direction of Dr. Mehmet Oz, and will officially go into effect on October 13. The provision will prevent federal Medicaid funds from covering puberty blockers, hormone treatments and gender-affirming surgeries for children under 18 years of age. In the case of CHIP, the restriction will apply to minors under 19 years of age.

The measure contemplates a transition for some patients

According to the Department of Health and Human Services (HHS), minors currently receiving hormonal treatments may continue to receive federally funded coverage during a transition period of up to six months after the rule goes into effect. This would allow some treatments to be maintained until April 2027. The Trump Administration maintains that the decision responds to a review of national and international research that, according to HHS and CMS, found important gaps in the available evidence on the benefits and risks of these interventions in minors.

Health and Human Services Secretary Robert F. Kennedy Jr. said the federal government will stop funding procedures that, in the Administration's opinion, may have permanent consequences and that do not have sufficient evidence to justify the use of public resources. Oz also defended the decision and assured that the objective is to protect minors and use taxpayer resources on treatments supported by scientific evidence.

However, gender-affirming care remains a controversial issue within the medical community. Professional organizations and specialists maintain different positions on the use of puberty blockers, hormones and other treatments in adolescents, while several countries and states have modified their policies on this type of care.

Trump expands his restrictions on gender care

The new policy adds to other actions taken by Trump since his return to the White House in January 2025 to limit gender-affirming treatments aimed at minors.

The Administration had already attempted to condition certain federal funds allocated to hospitals and medical centers to restrict the provision of these services. Since then, some health centers have suspended or limited certain treatments for minor patients.

The regulations announced this Tuesday do not eliminate federal coverage of mental health services for minors with gender dysphoria. HHS noted that Medicaid's Early and Periodic Screening, Diagnosis, and Treatment (EPSDT) provisions continue to ensure coverage of mental health services for eligible children. The measure specifically affects federal Medicaid and CHIP funds and represents another step by the Trump Administration to modify federal policy on treatments related to gender transition in minors.

This news has been tken from authentic news syndicates and agencies and only the wordings has been changed keeping the menaing intact. We have not done personal research yet and do not guarantee the complete genuinity and request you to verify from other sources too.